ImmPACT Bio USA Inc.

Oct 23, 2024

ImmPACT Bio to Present New Preclinical Data on Claudin18.2/TGF-b Bispecific CAR T-Cell Therapy IMPT-601 for Gastric Cancer at the SITC 39th Annual Meeting

Sep 25, 2024

ImmPACT Bio to Participate at the 2024 Cell and Gene Meeting on the Mesa Conference

Sep 17, 2024

ImmPACT Bio to Participate at Cell & Gene Therapy International 2024

Aug 21, 2024

ImmPACT Bio Announces FDA Clearance of IND Application for CD19/CD20 Bispecific CAR-T Cell Therapy in Multiple Sclerosis

Aug 14, 2024

ImmPACT Bio Appoints Ian Somaiya to its Board of Directors

May 21, 2024

ImmPACT Bio to Present New Preclinical Data for CD19/CD20 Bispecific CAR-T Cell Therapy in Multiple Sclerosis

Apr 22, 2024

ImmPACT Bio to Present New Ex Vivo Preclinical Data for Bispecific Claudin 18.2/TGF-b CAR T Program at the American Society of Gene & Cell Therapy 27th Annual Meeting

Feb 28, 2024

ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 Development of IMPT-514, a CD19/CD20 Bispecific CAR T-Cell Therapy for Refractory Lupus Nephritis and Systemic Lupus Erythematosus